Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Acarix, Balt, Cumberland, Hologic, Ingeneron, Oncolytics, TSC.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Ayrmid, Biodexa, Biomica, DT Cloud Star, Entera, Evogene, Invacare, Lishan, Opko, Otsuka, Primegen, T2 Biosystems, Zevra.
Clinical updates for biopharma and med tech, including data readouts and publications: Adagio Medical, Biogen, Immunic, Pharmazz, Spur, Theralase, Tr1x.
Biopharma and med-tech companies raising money in public or private financings, including: Biolab, Exxel, Imbed, Izotropic, Pavmed, Stratus, Third Arc.
New hires and promotions in the biopharma and med-tech industries, including: Aprea, Levicept, Lumicell, Mercy Bioanalytics, Nodthera, Providence Medical Technology, Rivus, United Imaging, Zoll.
The BioWorld Cancer Index closed 2025 up 72.35%, outpacing gains in the Nasdaq Biotechnology Index (up 32.4%) and the Dow Jones Industrial Average (up 12.97%). The year featured standout gains, led by Terns Pharmaceuticals Inc., which surged 620%.
The U.K.’s National Institute for Health and Care Excellence (NICE) has recommended the use of Abbott Laboratories’ Cardiomems HF system, giving people living with heart failure an option to monitor their condition daily from home. The implantable wireless sensor could transform care for individuals with the chronic condition as it will enable them to catch early warning signs before they escalate to medical emergencies.
In keeping with the congressional practice of passing major NIH reform legislation every 10 years, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee took the first step in looking at what can be for the NIH while unburdening it from what has been over the past few years.
After raising $61 million in a series B round, Vibrant Therapeutics Inc. is gearing up to begin a U.S. phase I trial with its lead program, VIB-305, a masked T-cell engager (TCE) for treating EGFR-positive solid tumors.
Pricing the third and largest biopharma IPO of 2026, Eikon Therapeutics Inc. raised $381 million in an upsized offering of 21.18 million shares of common stock at $18 each, the high point of its price range.
RSS
